SCHEMBL1635699

SCHEMBL1635699

CCN(CC)C(=O)c1cccc(C#C[Au])c1.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 0.48
TDP1 Q9NUW8 1/20 0.48
ALDH1A1 P00352 5/20 0.46
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 3/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TSHR P16473 1/20 0.41
PPARG P37231 1/20 0.40
OPRD1 P41143 1/20 0.39
CNR2 P34972 1/20 0.39
HSP90AA1 P07900 2/20 0.39
HSP90AB1 P08238 2/20 0.39
CYP1A2 P05177 1/20 0.39
BLM P54132 1/20 0.39
ADORA2A P29274 1/20 0.38
PDK2 Q15119 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1635695 0.82 ALDH1A1 (0.38) HPGDALDH1A1MAPTL3MBTL1LMNA
SCHEMBL1636978 0.82 ACACB (0.41) HPGDTDP1ALDH1A1MAPTNPC1
SCHEMBL1637052 0.80 ATM (0.49) HPGDTDP1ALDH1A1MAPTL3MBTL1
SCHEMBL1637036 0.79 ALDH1A1 (0.36) TDP1ALDH1A1MAPTLMNARAB9A
SCHEMBL1636089 0.79 ALDH1A1 (0.48) HPGDTDP1ALDH1A1MAPTL3MBTL1
SCHEMBL1636086 0.75 MAPT (0.43) TDP1ALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL1636350 0.75 TTR (0.40) HPGDTDP1ALDH1A1MAPTLMNA
SCHEMBL1637166 0.74 SMN1; SMN2 (0.42) HPGDTDP1ALDH1A1MAPTL3MBTL1
SCHEMBL1636094 0.73 HPGD (0.61) HPGDTDP1ALDH1A1MAPTL3MBTL1
SCHEMBL4918506 0.73 HPGD (0.61) HPGDTDP1ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2042506-B1 SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX UBE INDUSTRIES (JP) 2012-12-19 EP disclosed
US-7932398-B2 Substituted phenylethynylgold-nitrogen-containing heterocyclic carbene complex UBE INDUSTRIES, LTD. (JP) 2011-04-26 US disclosed
US-20090234130-A1 SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX UBE INDUSTRIES, LTD. (JP) 2009-09-17 US disclosed
EP-2042506-A1 SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX Ube Industries, Ltd. (JP) 2009-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234130-A1 SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX CCRL2, CCNL2, ATXN2L HPGD 3064/4885TDP1 4727/4885ALDH1A1 3101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.